Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2020 | ProPSMA: PSMA-PET/CT imaging for high risk prostate cancer

Michael Hofman • 18 Jul 2020
EAU 2020
Genitourinary Cancer Prostate Cancer

Michael Hofman, MBBS, FRACP, FAANMS, of the Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the results of the ProPSMA study, a prospective, randomized, multi-center trial of PSMA-PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Michael Hofman

1:26
[68Ga]Ga-DPI-4452, a novel CA IX-targeting peptide, in metastatic ccRCC
Michael Hofman • 25 Jan 2024
1:20
Advances in theranostics for prostate cancer
Michael Hofman • 25 Jan 2024
2:01
The emerging role of PET tracers in managing renal cell carcinoma
Michael Hofman • 25 Jan 2024
5:37
177Lu-PSMA-617 for the early treatment of prostate cancer
Michael Hofman • 16 Feb 2021

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals